SynthesisNeurosurgical review2026
Intraoperative radiotherapy for brain metastases after surgical resection a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases (BMs) are common in advanced cancers such as lung, breast, and melanoma, and carry a poor prognosis with high morbidity and local recurrence rates after surgery alone. Intraoperative radiotherapy (IORT) has emerged as a promising adjuvant treatment, delivering radiation directly to the resection cavity to reduce recurrence and minimize delays to systemic therapy. IORT also demonstrated more favorable dose homogeneity than single-fraction stereotactic radiosurgery, with fractionated IMRT achieving the highest uniformity. However, evidence regarding its efficacy and safety compared to non-IORT approaches remains limited. This meta-analysis synthesized data from 16 studies (2006-2023) involving 966 patients undergoing surgical resection of brain metastases, comparing outcomes between IORT (n = 616) and non-IORT (n = 350) groups. Key outcomes assessed included local control, overall survival (OS), distant brain control (DBC), postoperative complications, and adverse events. Meta-regression was used to explore associations between clinical factors and outcomes. IORT patients had significantly lower postoperative complication rates than non-IORT patients (risk ratio 0.52, 95% CI 0.43-0.62, p < 0.00001). Pooled local necrosis and postoperative mortality rates after IORT were low at 4.6% and 5.0%, respectively, with no significant variation by radiation dose or duration. The pooled local control rate (LCR) across eight studies was 92.5% (95% CI: 88.1-96.8%), despite moderate heterogeneity (I² = 65.4%, p = 0.005), highlighting IORT's effectiveness in local tumor control. IORT was also linked to shorter hospital stays (mean 8.8 vs. 19 days) and comparable or improved local recurrence rates. Meta-regression showed a positive correlation between lesion size and mortality (p < 0.05). Distant brain control averaged 52.4%, with moderate-to-low risk of bias across studies. IORT following surgical resection of brain metastases is a safe and effective modality, offering reduced postoperative complications and promising local control while enabling faster initiation of systemic therapy. Delivering adequate radiation doses tailored to tumor biology and size is critical to minimize local recurrence. Future clinical trials should focus on optimizing IORT parameters and establishing standardized guidelines to improve patient outcomes.
Indexed as
Identifiers
41545730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.